334 related articles for article (PubMed ID: 28419277)
1. Prevention of TB using rifampicin plus isoniazid reduces nevirapine concentrations in HIV-exposed infants.
McIlleron H; Denti P; Cohn S; Mashabela F; Hoffmann JD; Shembe S; Msandiwa R; Wiesner L; Velaphi S; Lala SG; Chaisson RE; Martinson N; Dooley KE;
J Antimicrob Chemother; 2017 Jul; 72(7):2028-2034. PubMed ID: 28419277
[TBL] [Abstract][Full Text] [Related]
2. Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.
; de Vincenzi I
Lancet Infect Dis; 2011 Mar; 11(3):171-80. PubMed ID: 21237718
[TBL] [Abstract][Full Text] [Related]
3. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
[TBL] [Abstract][Full Text] [Related]
4. Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial.
Jamieson DJ; Chasela CS; Hudgens MG; King CC; Kourtis AP; Kayira D; Hosseinipour MC; Kamwendo DD; Ellington SR; Wiener JB; Fiscus SA; Tegha G; Mofolo IA; Sichali DS; Adair LS; Knight RJ; Martinson F; Kacheche Z; Soko A; Hoffman I; van der Horst C;
Lancet; 2012 Jun; 379(9835):2449-2458. PubMed ID: 22541418
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, double-blind, placebo-controlled trial.
Coovadia HM; Brown ER; Fowler MG; Chipato T; Moodley D; Manji K; Musoke P; Stranix-Chibanda L; Chetty V; Fawzi W; Nakabiito C; Msweli L; Kisenge R; Guay L; Mwatha A; Lynn DJ; Eshleman SH; Richardson P; George K; Andrew P; Mofenson LM; Zwerski S; Maldonado Y;
Lancet; 2012 Jan; 379(9812):221-8. PubMed ID: 22196945
[TBL] [Abstract][Full Text] [Related]
6. Nevirapine plasma concentrations in premature infants exposed to single-dose nevirapine for prevention of mother-to-child transmission of HIV-1.
Mugabo P; Els I; Smith J; Rabie H; Smith P; Mirochnick M; Steyn W; Hall D; Madsen R; Cotton MF
S Afr Med J; 2011 Sep; 101(9):655-8. PubMed ID: 21920159
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of infants exposed to maternal tuberculosis and chemoprophylaxis using 3 months of isoniazid and rifampicin.
Mathivha KT; Velaphi S
Paediatr Int Child Health; 2017 May; 37(2):129-134. PubMed ID: 27455907
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of life.
Desmond AC; Moodley D; Conolly CA; Castel SA; Coovadia HM
BMC Pediatr; 2015 Mar; 15():23. PubMed ID: 25885678
[TBL] [Abstract][Full Text] [Related]
9. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: a randomized trial: the Mashi Study.
Thior I; Lockman S; Smeaton LM; Shapiro RL; Wester C; Heymann SJ; Gilbert PB; Stevens L; Peter T; Kim S; van Widenfelt E; Moffat C; Ndase P; Arimi P; Kebaabetswe P; Mazonde P; Makhema J; McIntosh K; Novitsky V; Lee TH; Marlink R; Lagakos S; Essex M;
JAMA; 2006 Aug; 296(7):794-805. PubMed ID: 16905785
[TBL] [Abstract][Full Text] [Related]
10. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002-2005.
Gupta A; Nayak U; Ram M; Bhosale R; Patil S; Basavraj A; Kakrani A; Philip S; Desai D; Sastry J; Bollinger RC;
Clin Infect Dis; 2007 Jul; 45(2):241-9. PubMed ID: 17578786
[TBL] [Abstract][Full Text] [Related]
11. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
Manosuthi W; Sungkanuparph S; Thakkinstian A; Rattanasiri S; Chaovavanich A; Prasithsirikul W; Likanonsakul S; Ruxrungtham K
Clin Infect Dis; 2006 Jul; 43(2):253-5. PubMed ID: 16779754
[TBL] [Abstract][Full Text] [Related]
12. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
Cohen K; van Cutsem G; Boulle A; McIlleron H; Goemaere E; Smith PJ; Maartens G
J Antimicrob Chemother; 2008 Feb; 61(2):389-93. PubMed ID: 18096560
[TBL] [Abstract][Full Text] [Related]
13. Non-nucleoside reverse transcriptase inhibitor levels among HIV-exposed uninfected infants at the time of HIV PCR testing - findings from a tertiary healthcare facility in Pretoria, South Africa.
Mazanderani AH; Murray TY; Sherman GG; Snyman T; George J; Avenant T; Goga AE; Pepper MS; du Plessis N
J Int AIDS Soc; 2019 Jun; 22(6):e25284. PubMed ID: 31215757
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Bhatt NB; Barau C; Amin A; Baudin E; Meggi B; Silva C; Furlan V; Grinsztejn B; Barrail-Tran A; Bonnet M; Taburet AM;
Antimicrob Agents Chemother; 2014 Jun; 58(6):3182-90. PubMed ID: 24663014
[TBL] [Abstract][Full Text] [Related]
15. Nevirapine pharmacokinetics in pregnant women and in their infants after in utero exposure.
Mirochnick M; Siminski S; Fenton T; Lugo M; Sullivan JL
Pediatr Infect Dis J; 2001 Aug; 20(8):803-5. PubMed ID: 11734746
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
17. Association of cord blood nevirapine concentration with reported timing of dose and HIV-1 transmission.
Jackson JB; Parsons T; Musoke P; Nakabiito C; Donnell D; Fleming T; Mirochnick M; Mofenson L; Fowler MG; Mmiro F; Guay L
AIDS; 2006 Jan; 20(2):217-22. PubMed ID: 16511414
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
Oudijk JM; McIlleron H; Mulenga V; Chintu C; Merry C; Walker AS; Cook A; Gibb DM; Burger DM
AIDS; 2012 Jul; 26(12):1523-8. PubMed ID: 22546991
[TBL] [Abstract][Full Text] [Related]
19. A randomized, double-blind, placebo-controlled trial of combined nevirapine and zidovudine compared with nevirapine alone in the prevention of perinatal transmission of HIV in Zimbabwe.
Thistle P; Spitzer RF; Glazier RH; Pilon R; Arbess G; Simor A; Boyle E; Chitsike I; Chipato T; Gottesman M; Silverman M
Clin Infect Dis; 2007 Jan; 44(1):111-9. PubMed ID: 17143826
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
